Silence Therapeutics (SLN) Other Non Operating Income (2024 - 2026)

Silence Therapeutics has disclosed Other Non Operating Income across 3 years of filings, most recently posting $571000.0 for Q1 2026.

• Other Non Operating Income for Q1 2026 came in at $571000.0, up 115.15% year-over-year; the trailing twelve-month figure through Mar 2026 was -$5.3 million (down 14797.22% YoY), and the FY2025 annual result was -$8.5 million, down 289.33% from the prior year.
• Other Non Operating Income came in at $571000.0 for Q1 2026 at Silence Therapeutics, up from -$19000.0 in the prior quarter.
• In the past five years, Other Non Operating Income ranged from a high of $1.4 million in Q3 2024 to a low of -$6.6 million in Q2 2025.
• The 3-year median for Other Non Operating Income is $571000.0 (2026), against an average of -$544888.9.
• Across the five-year window, Other Non Operating Income plunged 1173.79% in 2025 and jumped 115.15% in 2026, its largest moves.
• Silence Therapeutics' Other Non Operating Income stood at $1.0 million in 2024, then sank by 101.82% to -$19000.0 in 2025, then soared by 3105.26% to $571000.0 in 2026.
• The last three Other Non Operating Income figures came in at $571000.0 (Q1 2026), -$19000.0 (Q4 2025), and $770000.0 (Q3 2025), per Business Quant data.